


Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. (Currently Amended) A compound of the formula (I):




wherein

~~(i) X and Z represent both CH and Y represents nitrogen, forming a pyridine derivative, or~~

~~(ii) X represents C-CF<sub>3</sub>, Z represents CH, and Y represents nitrogen, forming a 4-trifluoromethylpyridine derivative, or~~

(iii) Y and Z represent both nitrogen and X represents CH, forming a pyrimidine derivative, and

wherein R<sub>1</sub> and R<sub>2</sub> are each, independently, selected from a group A consisting of



or from a group B, consisting of aryl-C<sub>1</sub>-C<sub>6</sub>-alkyl, aryl-C<sub>1</sub>-C<sub>6</sub>-alkoxy, heteroaryl-C<sub>1</sub>-C<sub>6</sub>-alkoxy, aryloxy-C<sub>2</sub>-C<sub>6</sub>-alkoxy, heteroaryloxy-C<sub>2</sub>-C<sub>6</sub>-alkoxy, 1-indanyloxy, 2-indanyloxy, aryloxy, heteroaryloxy, arylthio, heteroarylthio, C<sub>5</sub>-C<sub>6</sub>-cycloalkylthio, C<sub>5</sub>-C<sub>8</sub>-alkoxy, C<sub>5</sub>-C<sub>8</sub>-alkylthio, C<sub>3</sub>-C<sub>6</sub>-alkynyloxy, C<sub>3</sub>-C<sub>6</sub>-alkenyloxy, fluoro-C<sub>2</sub>-C<sub>4</sub>-alkoxy, C<sub>4</sub>-C<sub>8</sub>-cycloalkyloxy, C<sub>3</sub>-C<sub>8</sub>-cycloalkyl-

C<sub>1</sub>-C<sub>4</sub>-alkoxy, halogen, aryl-C<sub>1</sub>-C<sub>4</sub>-alkylthio, heteroaryl-C<sub>1</sub>-C<sub>4</sub>-alkylthio, aryl-C<sub>1</sub>-C<sub>4</sub>-alkylamino, heteroaryl-C<sub>1</sub>-C<sub>4</sub>-alkylamino, heteroaryl and aryl;

with the proviso that:

(i) R<sub>1</sub> and R<sub>2</sub> are different and are not both selected from group A or group B at the same time;  
(ii) ~~when both X and Z are CH and Y is N in formula (I), forming a pyridine derivative, and R<sub>1</sub> is 1-piperazinyl or 4-methylpiperazin-1-yl, then R<sub>2</sub> is other than 2-phenylethyl, benzyloxy, benzylamino, phenylthio, phenoxy, substituted phenoxy, C<sub>4</sub>-C<sub>8</sub>-cycloalkyloxy and C<sub>3</sub>-C<sub>8</sub>-cycloalkylmethoxy;~~

(iii) when X is CH and Z and Y both are nitrogen in formula (I), forming a pyrimidine derivative, and R<sub>2</sub> is 1-piperazinyl, then R<sub>1</sub> is other than phenoxy, phenyl or phenyl substituted by bromo, and C<sub>5</sub>-C<sub>8</sub> alkoxy; and when R<sub>2</sub> is 4-methylpiperazin-1-yl or 4-(2-hydroxyethyl)piperazin-1-yl, then R<sub>1</sub> is other than 5-nitro-2-furyl;

(iv) when X is CH and Z and Y both are nitrogen in formula (I), forming a pyrimidine derivative, and R<sub>1</sub> is 1-piperazinyl, then R<sub>2</sub> is other than C<sub>5</sub>-C<sub>8</sub> alkoxy;

and where R<sub>3</sub> is H or C<sub>1-4</sub>-alkyl, allyl, 2-hydroxyethyl, 2-cyanoethyl, or a nitrogen protecting group, ~~or a prodrug moiety;~~

R<sub>4</sub> is hydrogen, or C<sub>1-4</sub> alkyl;

and wherein any aryl or heteroaryl residue, alone or as part of another group, in R<sub>1</sub> or R<sub>2</sub> may be independently substituted in one or more positions, by C<sub>1-4</sub>-alkyl, C<sub>1-4</sub>-alkoxy, C<sub>1-4</sub>-alkylthio, C<sub>2-4</sub>-acyl, C<sub>1-4</sub>-alkylsulphonyl, cyano, nitro, hydroxy, C<sub>2-6</sub>-alkenyl, C<sub>2-6</sub>-alkynyl, fluoromethyl, trifluoromethyl, trifluoromethoxy, halogen, -N(R<sub>5</sub>)(R<sub>6</sub>), aryl, aryloxy, arylthio, aryl-C<sub>1-4</sub>-alkyl, aryl-C<sub>2-4</sub>-alkenyl, aryl-C<sub>2-4</sub>-alkynyl, heteroaryl, heteroaryloxy, heteroarylthio or heteroaryl-C<sub>1-4</sub>-alkyl, aryl-C<sub>1-4</sub>-alkoxy, aryloxy-C<sub>1-4</sub>-alkyl, dimethylamino-C<sub>2-4</sub>-alkoxy; and

wherein any aryl or heteroaryl residue as substituents on aryl or heteroaryl, alone or as part of another group, in R<sub>1</sub> or R<sub>2</sub> in turn may be substituted in one or more positions, independently of

each other by C<sub>1-4</sub>-alkyl, C<sub>1-4</sub>-alkoxy, halogen, trifluoromethyl, cyano, hydroxy or dimethylamino; and

R<sub>5</sub> and R<sub>6</sub> independently of each other are hydrogen, methyl or ethyl, or together with the nitrogen atom to which they are bound form a pyrrolidine, piperazine, morpholine, thiomorpholine or a piperidine ring;


~~and~~ or a pharmaceutically acceptable salt, ~~hydrate~~, geometrical isomer, tautomer, optical isomer, or ~~N-oxide or prodrug~~ form thereof.

2. (Withdrawn) The compound according to claim 1, wherein X and Z represent both CH and Y represents nitrogen, forming a pyridine derivative.


3. (Withdrawn) The compound according to claim 1, wherein formula (I) represents a 4-trifluoromethylpyridine derivative.

4. (Cancelled)

5. (Original) The compound according to claim 1 wherein R<sub>3</sub> is hydrogen and R<sub>1</sub> or R<sub>2</sub> is selected from




6. (Original) The compound according to claim 1 wherein R<sub>1</sub> or R<sub>2</sub> is selected from




and where R<sub>3</sub> is hydrogen and R<sub>4</sub> is selected from hydrogen, methyl or ethyl.

7. (Original) The compound according to claim 1 wherein R<sub>1</sub> or R<sub>2</sub> is



and where R<sub>3</sub> is hydrogen and R<sub>4</sub> is selected from hydrogen, methyl or ethyl.

8. (Original) The compound according to claim 1, wherein R<sub>1</sub> or R<sub>2</sub> is selected from



9. (Currently Amended) The compound according to claim 1, which is selected from the group consisting of:

4-(Benzyloxy)-2-(1-piperazinyl)pyrimidine,

4-[(2-Methoxybenzyl)oxy]-2-(1-piperazinyl)pyrimidine, and

2-[[3-(Benzyloxy)benzyl]oxy]-4-(1-piperazinyl)pyrimidine,

and or a their pharmacologically acceptable salts salt thereof and solvates.

10. (Original) A pharmaceutical composition comprising a compound according to claim 1 as an active ingredient, together with a pharmaceutically acceptable carrier.

11. (Cancelled) .

12. (Cancelled)

13. (Currently Amended) A The method for the treatment of according to claim 11, wherein the medical condition is an eating disorder, comprising administering to a subject in need thereof a therapeutically effective amount of a compound according to claim 1.

14. (Currently Amended) A The method for the treatment of according to claim 11, wherein the medical condition is obesity, comprising administering to a subject in need thereof a therapeutically effective amount of a compound according to claim 1.

15. (Currently Amended) A The method for the treatment of according to claim 11, wherein the medical condition is a memory disorder, comprising administering to a subject in need thereof a therapeutically effective amount of a compound according to claim 1.

16. (Currently Amended) A The method for the treatment of according to claim 11, wherein the medical condition is a mood disorder, comprising administering to a subject in need thereof a therapeutically effective amount of a compound according to claim 1.

17. (Currently Amended) A The method for the treatment of according to claim 11, wherein the medical condition is an anxiety disorder, comprising administering to a subject in need thereof a therapeutically effective amount of a compound according to claim 1.

18. (Currently Amended) A The method for the treatment of according to claim 11, wherein the medical condition is selected from sexual dysfunctions, epilepsy and or urinary

disorders, comprising administering to a subject in need thereof a therapeutically effective amount of a compound according to claim 1.


19. (Currently Amended) ~~A The method for the treatment of according to claim 11, wherein the medical condition is pain, comprising administering to a subject in need thereof a therapeutically effective amount of a compound according to claim 1.~~

20. (Currently Amended) ~~A The method for the treatment of according to claim 11, wherein the medical condition is substance abuse, comprising administering to a subject in need thereof a therapeutically effective amount of a compound according to claim 1.~~

21. (Currently Amended) ~~A The method for the treatment of according to claim 11, wherein the medical condition is schizophrenia, comprising administering to a subject in need thereof a therapeutically effective amount of a compound according to claim 1.~~

22. (Currently Amended) A method of making a compound of claim 1, the method comprising:

(a) taking converting a compound of the following formula:



wherein


(i) X and Z represent both CH and Y represents nitrogen, forming a pyridine derivative, or

(ii) X represents C-CF<sub>3</sub>, Z represents CH, and Y represents nitrogen, forming a 4-trifluoromethylpyridine derivative, or


(iii) Y and Z represent both nitrogen and X represents CH, forming a pyrimidine derivative, and  
wherein

each Hal is independently a halogen;


to a compound of formula (IX):



wherein R<sub>2</sub> is as defined in claim 1 and with the proviso that R<sub>2</sub> is not any of the following groups:




(b) contacting the compound of formula (IX) with a compound selected from the group consisting of:




or


(a') converting a compound of the following formula:



wherein Y and Z represent both nitrogen and X represents CH, forming a pyrimidine derivative, and wherein each Hal is independently a halogen;  
to a compound of formula (XIII):




wherein Am is an amine residue selected from the group consisting of:






(b') converting the compound of formula (XIII) to a compound of the following formula:



wherein R<sub>1</sub> is as defined in claim 1 and with the proviso that R<sub>1</sub> is not any of the following groups:



~~with and reacting the compound with one or more chemical reagents in one or more steps to produce thereby producing~~ a compound of claim 1.

23. (Cancelled)
24. (Cancelled)
25. (Original) The compound according to claim 1, wherein R<sub>3</sub> is an acyl- or alkoxycarbonyl group forming a cleavable amide or carbamate linkage.
26. (New) The method of claim 15, wherein the memory disorder is Alzheimer's disease.
27. (New) The method of claim 16, wherein the mood disorder is depression.